MedCity News January 19, 2025
While advancements in diagnostics are promising, the need remains for healthcare professionals to take the lead on proactive conversations with patients and their loved ones about the early signs and symptoms of Alzheimer’s disease.
Over the last two years, we’ve seen some of the most impactful scientific advancements in Alzheimer’s disease diagnostics and treatment compared to recent decades. With more accessible means of confirming Alzheimer’s disease pathology and the availability of amyloid-targeting therapies, we’re finally equipped to target the underlying pathology and help slow the cognitive and functional decline caused by this disease.
Amyloid-targeting therapies are currently FDA-approved for early symptomatic Alzheimer’s disease, and it is important to note that according to recent studies, the earlier treatment is...
Today's Sponsors
Today's Sponsor